Loading
Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.
Camizestrant is AstraZeneca's next-generation oral SERD. SERENA-6 randomised patients whose ctDNA acquired an ESR1 mutation during first-line AI + CDK4/6 to switch to camizestrant + CDK4/6: PFS 16.0 vs 9.2 months (HR 0.44). After a 6-3 negative ODAC vote (April 2026) over the clinical meaning of acting on ctDNA, FDA granted accelerated approval on 4 September 2026, the first indication triggered by a molecular rather than radiographic event. SERENA-4 (first-line, unselected) and the adjuvant CAMBRIA trials will define its wider role.
Oral SERD: ER antagonist and degrader active against wild-type and ESR1-mutant receptors. Connects to Estrogen receptor (ERα).
1.Serial ctDNA detects an ESR1 mutation while scans still show control
Sources: NICE search: camizestrant. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
NDA based on SERENA-6
ODAC voted 6-3 against (clinical relevance of ctDNA-triggered switch) source
In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test
Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read. source
| Region | Year | Indication |
|---|---|---|
| US | 2026 | HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026) |
| EU | 2026 | ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026 |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Photopsia (visual flashes) class effect, reversible | 20% | - |
| Bradycardia | 15% | - |
| Neutropenia (with CDK4/6) largely from the CDK4/6 partner | - | 45% |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Camizestrant" OR ABSTRACT:"Camizestrant" OR TITLE:"Etcamah" OR ABSTRACT:"Etcamah" OR TITLE:"AZD9833" OR ABSTRACT:"AZD9833") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Camizestrant, not a curated reading list.
Shares Oral SERD + CDK4/6 inhibitor after ESR1 emergence, Oral SERDs, Oral SERD, ESR1 mutation (ligand-binding domain, usually in ctDNA).
Shares Oral SERD + CDK4/6 inhibitor after ESR1 emergence, Oral SERD, ESR1 mutation, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
Shares Oral SERDs, Oral SERD, Intercepting late recurrence with ctDNA surveillance and oral SERDs, High-risk early HR-positive breast cancer.
Shares Oral SERDs, Oral SERD, ESR1 mutation (ligand-binding domain, usually in ctDNA), ESR1 mutation.
Shares Oral SERDs, ESR1 mutation, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor (ERα).
Shares ESR1 mutation, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor (ERα), Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test.
Shares High-risk early HR-positive breast cancer, Estrogen receptor (ERα), Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs).
Shares ESR1 mutation (ligand-binding domain, usually in ctDNA), SERENA-6, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).